| Autor: |
Magnus Bein, Myriam Lesage, Elena Dikaios, Mallar Chakravarty, Zindel Segal, Isabelle Royal, Mark Speechley, Alessandra Schiavetto, Daniel Blumberger, Matthew D. Sacchet, Joseph Therriault, Johanna Gruber, Valerie Tourjman, Stephane Richard-Devantoy, Vasavan Nair, Marie-Andrée Bruneau, Soham Rej, Michael Lifshitz, Harmehr Sekhon |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Frontiers in Aging Neuroscience, Vol 14 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
1663-4365 |
| DOI: |
10.3389/fnagi.2022.976636 |
| Popis: |
BackgroundLate-life depression (LLD) affects up to 18% of older adults and has been linked to elevated dementia risk. Mindfulness-based cognitive therapy (MBCT) holds promise for treating symptoms of depression and ameliorating cognitive deficits in older adults. While preliminary findings are promising, a definitive RCT investigating its effects on late life depression and cognition have not yet been conducted. We present a protocol describing a multi-site blinded randomized controlled trial, comparing the effects of MBCT and of an active control, a Health Enhancement Program (HEP), on depressive symptoms, executive functioning, and brain biomarkers of LLD, among several other exploratory outcomes.MethodsTwo-hundred and thirteen (n = 213) patients with LLD will be recruited at various centers in Montreal, QC, Canada. Participants will undergo stratified randomization to either MBCT or HEP intervention groups. We will assess changes in (1) depression severity using the Hamilton Depression Rating Scale (HAM-D17), (2) processing speed and executive functioning, (3) brain biomarkers of LLD (hippocampal volume, default network resting-state functional connectivity and executive network resting-state functional connectivity), and (4) other exploratory physiological and mood-based measures, at baseline (0 weeks), post intervention (8 weeks), and 26 weeks after baseline.DiscussionThe proposed study will assess the clinical potential of MBCT to improve symptoms of depression, as well as examine its impact on cognitive impairments and neurobiological markers, and thus inform its use as a promising adjunct in the treatment of LLD.Clinical trial registrationwww.ClinicalTrials.gov, identifier: NCT05366088. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
